EUVIMEDOpdag EUVIMED
Crossref

ERG and PTEN Role on Active Surveillance for Low‐Risk Prostate Cancer in the Multiparametric MRI Era

Marco Aurelio Watanabe Yorioka iD, Claudio Bovolenta Murta iD, Kátia Ramos Moreira Leite, Leonardo Cardili, Evandro Sobroza de Mello, Arnaldo Jose de Carvalho Fazoli, Maurício Dener Cordeiro, Rafael Ferreira Coelho, Públio Cesar Cavalcante Viana, Cesar Sadao Nicolino Kohama, William Carlos Nahas, José Pontes-Júnior

The Prostate · 2025

DOI: 10.1002/pros.24835 ↗

At a glance

Journal article in The Prostate, 2025. Written by Marco Aurelio Watanabe Yorioka and 11 co-authors. Institution: Urology Department, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil. Major MEDLINE topics: Prostatic Neoplasms, Transcriptional Regulator ERG, PTEN Phosphohydrolase, Multiparametric Magnetic Resonance Imaging. Cited 4 times so far (Crossref); 27 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Our study aimed to correlate ERG and PTEN expressions in prostate biopsy with multiparametric magnetic resonance imaging PI‐RADS score, clinical reclassification, and prognosis of very low‐risk prostate cancer (PCa) patients under active surveillance (AS).

Methods

We evaluated 101 very low‐risk PCa patients under AS between 2013 and 2018. They were followed with DRE, PSA, MRI, and re‐biopsies every 1–2 years. Per cause biopsy was recommended if PSA > 10 ng/mL, suspicious DRE, or PI‐RADS ≥ 4 was present. ERG and PTEN expressions were assessed by immunohistochemistry at biopsy. Reclassification was defined by PSA > 10 ng/mL, re‐biopsy with > 3 positive cores, > 50% positive core, Gleason Score (GS) upgrading ≥ 3 + 4 or extreme GS upgrading ≥ 4 + 3. We correlated ERG and PTEN with reclassification, PI‐RADS, pathologic outcomes, and biochemical recurrence in patients surgically treated after reclassification.

Results

After a 49.2‐month follow‐up, 80% of patients showed reclassification, and GS upgrading was the most common criterion. Seventy‐four out of 81 patients with reclassification underwent local treatment and seven had biochemical recurrence during a mean 39.7‐month follow‐up. At biopsy, positive ERG expression was found in 39.6% of patients and PTEN loss in 12.6%. PTEN loss was associated with GS upgrading (OR = 9.7, p = 0.011) in univariate analysis. PTEN loss was correlated with GS upgrading; these patients had a 9.7‐fold greater chance of upgrading when compared to PTEN‐positive patients. ERG‐positive was associated with PI‐RADS ≥ 4 (OR = 2.8, p = 0.026). At multivariate analysis, PI‐RADS ≥ 4 was predictor of GS upgrading (OR = 25.2, p < 0.001); MRI PI‐RADS score remained an independent factor for extreme GS upgrading, together with PSAd > 0.15 (OR = 15.1, p = 0.012 and OR = 5.76, p = 0.012, respectively).

Conclusions

Neither ERG‐positive nor PTEN loss were associated with upgrading during AS. ERG and PTEN biomarkers, despite commonly studied in advanced PCa, have yet no defined role in very low‐risk PCa under AS. PI‐RADS score was an independent predictor of GS upgrading and extreme upgrading during AS.

Subjects

MeSH terms (MEDLINE)

Prostatic NeoplasmsTranscriptional Regulator ERGPTEN PhosphohydrolaseMultiparametric Magnetic Resonance ImagingWatchful WaitingHumansMaleMiddle AgedAgedNeoplasm GradingPrognosisProstateBiomarkers, Tumor

Author keywords

PTEN proteinactive surveillancemultiparametric MRIprostate cancertransforming protein ERG

Substances

Transcriptional Regulator ERGPTEN PhosphohydrolaseERG protein, humanPTEN protein, humanBiomarkers, Tumor

Authors and institutions

  • Urology Department, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.
  • Pathology Department, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.
  • Radiology Department, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

ORCID profiles: Marco Aurelio Watanabe Yorioka, Claudio Bovolenta Murta

Cite

APA

Yorioka, M. A. W., Murta, C. B., Leite, K. R. M., Cardili, L., de Mello, E. S., de Carvalho Fazoli, A. J., Cordeiro, M. D., Coelho, R. F., Viana, P. C. C., Kohama, C. S. N., Nahas, W. C., & Pontes-Júnior, J. (2025). ERG and PTEN Role on Active Surveillance for Low‐Risk Prostate Cancer in the Multiparametric MRI Era. The Prostate. https://doi.org/10.1002/pros.24835

Vancouver

Yorioka MAW, Murta CB, Leite KRM, Cardili L, de Mello ES, de Carvalho Fazoli AJ, et al. ERG and PTEN Role on Active Surveillance for Low‐Risk Prostate Cancer in the Multiparametric MRI Era. The Prostate. 2025. doi:10.1002/pros.24835

BibTeX
@article{Yorioka2025,
  author = {Yorioka, Marco Aurelio Watanabe and Murta, Claudio Bovolenta and Leite, Kátia Ramos Moreira and Cardili, Leonardo and de Mello, Evandro Sobroza and de Carvalho Fazoli, Arnaldo Jose and Cordeiro, Maurício Dener and Coelho, Rafael Ferreira and Viana, Públio Cesar Cavalcante and Kohama, Cesar Sadao Nicolino and Nahas, William Carlos and Pontes-Júnior, José},
  title = {ERG and PTEN Role on Active Surveillance for Low‐Risk Prostate Cancer in the Multiparametric MRI Era},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24835}
}
Start for free →